ATH 0.00% 0.3¢ alterity therapeutics limited

pbt and alzheimers

  1. 5,929 Posts.
    lightbulb Created with Sketch. 151
    Current #1 Alzheimers drug earns $2.3 Billion per year on 30% of the US market
    http://www.reuters.com/article/health-SP/idUST28743820070717
    Prana was founded by the scientists who identified that plaques, caused by a combination of copper and zinc, forming on the brain cause alzheimers. They are world leaders in their field.
    They have been working on ridding the brain of these palques, and have already done so in mice, restoring memory.
    The first drug they came up with contained impurities which caused complications and the clinical trial was cancelled.
    The next drug they came up with was pure and passed the phase 1 safety trial OK on healthy patients.
    Now it is in a double blind phase 2 trial on Alzheimer patients which will be complete in December, and if the good doctors running Prana are right, this little co could possibly be worth many times its current price IMHO.
    The best current drug, Aricept, earns $2.3B yet only supplies 30% of the US market. A drug that could stop Alzheimers and even reverse it would see a much larger market share.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
0.000(0.00%)
Mkt cap ! $15.96M
Open High Low Value Volume
0.3¢ 0.4¢ 0.3¢ $12.53K 4.143M

Buyers (Bids)

No. Vol. Price($)
3 13926044 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 153031722 56
View Market Depth
Last trade - 14.56pm 19/11/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.